Skip to main content
Assets
Pfizer logo
PFE.NYSE
Pfizer
Health Care · Pharmaceuticals

Global pharmaceutical company developing vaccines and medicines for oncology, inflammation, cardiovascular, and rare diseases including COVID-19 vaccine.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Pfizer.

Historical AI Opinions

Pfizer Inc. (PFE.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts

AI Advisor 1 AI

Independent Investor FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+88.6%

Includes 4.35% annual net dividend contribution

1. Investment Thesis — Base Case

The most reasonable thesis projects a stabilization and gradual recovery. While the COVID-19 revenue boom has evaporated and patent cliffs for major blockbusters like Ibrance and Eliquis present significant headwinds between 2026 and 2028, Pfizer's massive scale, aggressive cost-cutting, and the accretive revenue from Seagen provide a solid floor. The stock is currently priced for zero growth; therefore, modest pipeline successes in oncology and immunology, combined with a secure and attractive (~5-6%), will drive total returns. We expect the stock to grind higher as earnings quality improves and the market digests the post-COVID reset, re-rating slowly from depressed levels to a fair value range of 12x-13x by 2030.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.18.0729.7541.4353.1164.79Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2020-11-2537.2
Observed price2020-12-0640.9
Observed price2020-12-2236.8
Observed price2021-01-0737.4
Observed price2021-01-1836.6
Observed price2021-01-2835.9
Observed price2021-02-2433.7
Observed price2021-03-0234.0
Observed price2021-03-2836.3
Observed price2021-04-0836.1
Observed price2021-04-1938.8
Observed price2021-05-0540.0
Observed price2021-05-3139.0
Observed price2021-06-1140.3
Observed price2021-06-2739.1
Observed price2021-07-0839.6
Observed price2021-08-0444.5
Observed price2021-08-0946.3
Observed price2021-08-2049.0
Observed price2021-09-1045.5
Observed price2021-10-0742.4
Observed price2021-10-1241.9
Observed price2021-11-0849.5
Observed price2021-11-1350.5
Observed price2021-11-2953.6
Observed price2021-12-1560.9
Observed price2022-01-0655.1
Observed price2022-01-1654.1
Observed price2022-02-1250.3
Observed price2022-02-2847.8
Observed price2022-03-1652.7
Observed price2022-03-2153.8
Observed price2022-04-1750.7
Observed price2022-05-0348.6
Observed price2022-05-1952.1
Observed price2022-05-3053.6
Observed price2022-06-1548.6
Observed price2022-06-2650.2
Observed price2022-07-1252.5
Observed price2022-07-2851.6
Observed price2022-08-2447.4
Observed price2022-09-0946.8
Observed price2022-09-2544.5
Observed price2022-10-1142.1
Observed price2022-10-2746.4
Observed price2022-11-0647.1
Observed price2022-11-2849.8
Observed price2022-12-0349.9
Observed price2022-12-1451.7
Observed price2023-01-0449.7
Observed price2023-01-3143.7
Observed price2023-02-0543.7
Observed price2023-02-2740.8
Observed price2023-03-0939.5
Observed price2023-04-0541.5
Observed price2023-04-1041.6
Observed price2023-05-0738.7
Observed price2023-05-1836.6
Observed price2023-06-0839.1
Observed price2023-06-1440.0
Observed price2023-07-0535.7
Observed price2023-07-2137.0
Observed price2023-08-0135.3
Observed price2023-08-2236.8
Observed price2023-09-1234.1
Observed price2023-09-1834.0
Observed price2023-10-1432.9
Observed price2023-10-2031.7
Observed price2023-11-1629.5
Observed price2023-11-2630.1
Observed price2023-12-1226.7
Observed price2024-01-0329.7
Observed price2024-01-1928.3
Observed price2024-01-2427.8
Observed price2024-01-2927.2
Observed price2024-03-0126.8
Observed price2024-03-1228.0
Observed price2024-03-2827.6
Observed price2024-04-2425.7
Observed price2024-04-2926.9
Observed price2024-05-2628.8
Observed price2024-06-0628.8
Observed price2024-06-1627.5
Observed price2024-07-0828.0
Observed price2024-07-2931.3
Observed price2024-08-0430.0
Observed price2024-08-3028.5
Observed price2024-09-0528.7
Observed price2024-09-1529.5
Observed price2024-10-1729.2
Observed price2024-11-0227.9
Observed price2024-11-0826.7
Observed price2024-11-1825.1
Observed price2024-12-1525.7
Observed price2025-01-0626.8
Observed price2025-01-2726.7
Observed price2025-02-0725.7
Observed price2025-02-1225.6
Observed price2025-03-1126.4
Observed price2025-03-1625.9
Observed price2025-04-1222.0
Observed price2025-04-1722.2
Observed price2025-04-2824.0
Observed price2025-05-1923.0
Observed price2025-06-1524.4
Observed price2025-06-2024.1
Observed price2025-07-0625.6
Observed price2025-08-0223.7
Observed price2025-08-1825.3
Observed price2025-08-2325.2
Observed price2025-09-1924.1
Observed price2025-09-2524.0
Observed price2025-10-0526.4
Observed price2025-11-0624.5
Observed price2025-11-1225.9
Observed price2025-12-0825.9
Observed price2025-12-2424.9
Observed price2025-12-3025.0
Observed price2026-01-2026.0
Observed price2026-01-3126.4
Observed price2026-02-2727.6
Observed price2026-03-0426.7
Observed price2026-03-3127.9
Observed price2026-04-0527.8
Observed price2026-05-0226.4
Observed price2026-05-0726.0
Observed price2026-05-1825.7
Observed price2026-06-0826.1
Observed price2026-07-0523.8
Observed price2026-07-1024.2
Observed price2026-08-0626.4
Observed price2026-08-1126.4
Observed price2026-09-0229.0
Observed price2026-09-1427.7
Observed price2026-09-1627.5
Observed price2026-09-1827.7
Published advisor forecast2025-11-2625.7
Published advisor forecast2026-05-2727.1
Published advisor forecast2026-11-2728.4
Published advisor forecast2027-05-2729.8
Published advisor forecast2027-11-2731.2
Published advisor forecast2028-05-2732.5
Published advisor forecast2028-11-2733.7
Published advisor forecast2029-05-2735.1
Published advisor forecast2029-11-2736.4
Published advisor forecast2030-05-2737.8
Published advisor forecast2030-11-2739.2

2. Scenarios & Signals

Bull case

In the bull case, Pfizer successfully executes its 'oncology pivot' following the Seagen integration, with the cancer portfolio delivering double-digit growth that significantly outweighs the impact of for Ibrance and Eliquis. The company's pipeline delivers a best-in-class oral or similar metabolic asset, re-rating the stock to peer multiples closer to 15x-16x P/E. Cost realignment programs exceed targets, boosting back above 35%. Macroeconomically, a lower interest rate environment in 2026-2028 drives investors back to high-yield defensive stocks, compressing Pfizer's and driving . By 2030, Pfizer re-establishes itself as a growth pharmaceutical company rather than a .

Bear case

The bear case assumes the '' ( for Eliquis, Ibrance, Xeljanz) erodes revenue faster than the pipeline can replenish it. The Seagen acquisition fails to generate expected due to competitive pressure in the ADC (Antibody-Drug Conjugate) space. Pfizer's attempts to enter the obesity market fail clinically or commercially. Legal liabilities related to legacy products or new unforeseen litigation weigh on cash flow, forcing a dividend cut or suspension of buybacks. Persistently high inflation or interest rates make risk-free bonds more attractive than Pfizer's dividend, causing the stock to de-rate to historically low multiples (8x-9x P/E) and languish in the low $20s or teens.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus